RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 123 filers reported holding RHYTHM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $5,197,042 | -1.2% | 291,314 | +61.3% | 0.02% | -21.4% |
| Q4 2022 | $5,257,820 | +4318.3% | 180,557 | +527.1% | 0.03% | +2700.0% |
| Q2 2022 | $119,000 | -41.1% | 28,794 | +86.3% | 0.00% | -66.7% |
| Q3 2021 | $202,000 | -55.6% | 15,453 | -33.5% | 0.00% | -40.0% |
| Q2 2021 | $455,000 | -19.8% | 23,224 | -12.9% | 0.01% | -44.4% |
| Q1 2021 | $567,000 | +72.3% | 26,676 | +75.7% | 0.01% | +80.0% |
| Q3 2020 | $329,000 | – | 15,183 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |